Y
Yayi He
Researcher at Tongji University
Publications - 117
Citations - 2597
Yayi He is an academic researcher from Tongji University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 20, co-authored 107 publications receiving 1421 citations. Previous affiliations of Yayi He include Kindai University & Anschutz Medical Campus.
Papers
More filters
Journal ArticleDOI
cGAS-STING, an important pathway in cancer immunotherapy
Minlin Jiang,Peixin Chen,Lei Wang,Wei Li,Bin Chen,Yu Liu,Hao Wang,Sha Zhao,Lingyun Ye,Yayi He,Caicun Zhou +10 more
TL;DR: The biological characters, current applications, challenges, and future directions of cGAS-STING in cancer immunotherapy are examined.
Journal ArticleDOI
LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
Yayi He,Hui Yu,Leslie Rozeboom,Christopher J. Rivard,Kim Ellison,Rafal Dziadziuszko,Kenichi Suda,Shengxiang Ren,Chunyan Wu,Likun Hou,Caicun Zhou,Fred R. Hirsch +11 more
TL;DR: It is found that patients with both PD‐L1–negative tumor cells and LAG‐3–negative TILs have longer recurrence‐free survival than patients who are either PD‐ L1– or LAG–3–positive or both PD-L1- and Lag‐3‐positive.
Journal ArticleDOI
Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer
Fengying Wu,Jue Fan,Yayi He,Anwen Xiong,Jia Yu,Yixin Li,Yan Zhang,Wencheng Zhao,Fei Zhou,Wei Li,Jie Zhang,Xiaosheng Zhang,Meng Qiao,Guanghui Gao,Shanhao Chen,Xiaoxia Chen,Xuefei Li,Likun Hou,Chunyan Wu,Chunxia Su,Shengxiang Ren,Margarete Odenthal,Reinhard Buettner,Nan Fang,Caicun Zhou +24 more
TL;DR: In this paper, the authors analyzed 42 tissue biopsy samples from stage III/IV NSCLC patients by single cell RNA sequencing and presented the large scale, single cell resolution profiles of advanced NSCLCs.
Journal ArticleDOI
TIM-3, a promising target for cancer immunotherapy.
TL;DR: The role of TIM-3 in cancer and clinical trials with TIM- 3 inhibitors is reviewed and a promising approach for cancer immunotherapy is targeted.
Journal ArticleDOI
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
Bing Li,Shengxiang Ren,Xuefei Li,Yongsheng Wang,David Garfield,Songwen Zhou,Xiaoxia Chen,Chunxia Su,Mo Chen,Peng Kuang,Guanghui Gao,Yayi He,Lihong Fan,Ke Fei,Caicun Zhou,Gerald Schmit-Bindert +15 more
TL;DR: In this article, miR-21 was found to be involved in acquired resistance of EGFR-TKI in NSCLC, which is mediated by down-regulating PTEN and PDCD4 and activating PI3K/Akt pathway.